Heparin Therapy in Unstable Angina

Indications & Core Recommendation

• Heparin should be administered to all patients with unstable angina unless contraindicated, and it must be combined with aspirin. The American Heart Association (AHA) specifies this as standard of care for acute myocardial ischemia. 1
• Adding aspirin to heparin reduces cardiovascular death and myocardial infarction by ≈30 % compared with aspirin alone in unstable angina. In pooled trial data, myocardial infarction fell from 11.9 % with aspirin alone to 1.6 % with the combination (P = 0.001). 1

Efficacy of Heparin (Unfractionated)

• Heparin alone lowers the incidence of myocardial infarction from 11.9 % to 0.8 % (P < 0.0001). 1
• Heparin alone reduces refractory angina from 22.9 % to 8.5 % (P = 0.002). 1
• Meta‑analysis of six randomized trials shows the heparin + aspirin regimen decreases the composite of death or myocardial infarction from 10.3 % to 7.9 % (absolute risk reduction = 2.4 %; odds ratio = 0.74). Evidence level: high (multiple RCTs). 2

Dosing, Monitoring, and Treatment Duration

• Initial intravenous bolus: 60–70 units/kg (maximum 5,000 U).
• Continuous infusion: 12–15 units/kg/h, titrated to achieve an activated partial thromboplastin time (aPTT) of 1.5–2.0 × control (or an absolute value of 50–70 seconds).** AHA‑endorsed therapeutic target. 1
• Alternative protocol (landmark trials): 5,000 U IV bolus followed by 1,000 U/h infusion, adjusted to maintain therapeutic aPTT. 1
• Treatment course: approximately 5–6 days of continuous heparin infusion. 1

Timing of Initiation

• Heparin should be started within 24 hours of symptom onset for patients presenting with unstable angina, based on clinical presentation and ECG findings rather than waiting for troponin results. 1

High‑Risk Clinical Features Prompting Immediate Anticoagulation

• Recurrent chest pain despite initial therapy.
• Hemodynamic instability (e.g., hypotension, shock).
• Major arrhythmias (e.g., ventricular tachycardia/fibrillation).

Low‑Molecular‑Weight Heparin (LMWH) as an Alternative

• Enoxaparin can replace unfractionated heparin; evidence suggests it may be superior. The ESSENCE trial demonstrated a 16 % relative reduction in the composite of death, myocardial infarction, and recurrent angina versus standard unfractionated heparin. 2
• Practical advantages of LMWH: subcutaneous delivery, no routine laboratory monitoring, and more predictable anticoagulant effect. 2

Interaction with Other Antithrombotic Therapies

• When glycoprotein IIb/IIIa inhibitors or thrombolytics are used, the heparin dose should be reduced (with defined maximum caps) to lower bleeding risk. This recommendation is endorsed by the AHA. 1

Contraindications to Heparin Use

• Active bleeding or hemorrhagic diathesis.
• Heparin‑induced thrombocytopenia (alternative: direct thrombin inhibitors).
• Severe uncontrolled hypertension.

Aspirin and Heparin Combination Therapy in Acute Coronary Syndromes

Evidence-Based Rationale

• The American Heart Association guidelines explicitly state that heparin is always used in combination with aspirin in patients with acute myocardial ischemia, those receiving thrombolytic therapy, those treated with GP IIb/IIIa antagonists for unstable angina, and those undergoing high-risk coronary angioplasty. 4, 5, 6
• In unstable angina patients, the combination of aspirin plus heparin reduced myocardial infarction rates to 1.6% compared to 11.9% with placebo, and this benefit was statistically significant (P=0.001). 4, 5, 6
• Meta-analysis of 6 randomized trials demonstrated that aspirin plus heparin reduces short-term rates of cardiovascular death and MI by approximately 30% over aspirin alone. 4, 5

Clinical Outcomes with Combination Therapy

• In the setting of coronary thrombolysis with aspirin, adding heparin provides modest additional benefit: 5 fewer deaths per 1000 patients (P=0.03), 3 fewer reinfarctions per 1000 (P=0.04), and 1 fewer pulmonary embolism per 1000 (P=0.01). 7, 8, 9, 10, 11
• A meta-analysis found the relative risk of MI or death was 0.67 (95% CI 0.44-1.02) with aspirin plus heparin compared to aspirin alone in unstable angina, consistent with a 33% risk reduction.

Critical Bleeding Risk Considerations

• The combination increases major bleeding by 3 additional events per 1000 patients (P<0.0001) compared to aspirin alone in the thrombolysis setting. 7, 8, 9, 10, 11
• In high-dose heparin regimens combined with aspirin, major extracranial bleeding increased approximately 2-fold (2.3% vs 1.1%; P=0.01). 7, 8

Monitoring Requirements

• Close monitoring of aPTT is essential, with target range of 1.5-2.0 times control (or 50-70 seconds absolute) when combining heparin with aspirin. 4, 5, 6

Common Pitfalls to Avoid

• Do not withhold aspirin in patients on heparin drips for acute coronary syndromes—the combination is evidence-based standard of care despite increased bleeding risk. 4, 5, 6
• Do not assume that bleeding risk precludes combination therapy—the mortality and MI reduction benefits typically outweigh the bleeding risk in appropriate clinical contexts (acute coronary syndromes, unstable angina). 4, 5, 6, 7, 8, 9

Heparin Use in Troponin‑Negative Acute Coronary Syndromes

Combination Anticoagulation Strategy

• In patients with acute myocardial ischemia, heparin should always be administered together with aspirin; this dual therapy lowers cardiovascular death and myocardial infarction by roughly 30 % compared with aspirin alone in unstable‑angina cohorts. 12

Indications for Heparin in Troponin‑Negative Patients

Low‑Risk Patients

• The European Society of Cardiology (ESC) recommends that all patients without ST‑segment elevation receive immediate baseline therapy—including aspirin, unfractionated heparin, β‑blockers, and nitrates—irrespective of the initial troponin result. 13

High‑Risk Features Requiring Immediate Heparin (even when troponin is negative)

• Presence of any of the following mandates prompt heparin initiation:

Monitoring and Discontinuation Criteria

• Troponin should be re‑measured 6–12 hours after presentation; heparin may be stopped only after two consecutive negative troponin results (at presentation and at 6–12 h) and when the patient is low‑risk (no recurrent pain, a normal or minimally abnormal ECG, and absence of high‑risk clinical features). 13

• For low‑risk patients who meet all of the following, heparin can be discontinued after the initial course:

• Troponin negativity alone does not exclude acute coronary syndrome, because biomarker elevation may be delayed up to 6–12 hours after symptom onset; unstable angina is defined by negative troponins yet still requires anticoagulation. 13

Alternative Anticoagulant: Low‑Molecular‑Weight Heparin

• Enoxaparin (a low‑molecular‑weight heparin) can replace unfractionated heparin; it provides subcutaneous administration, eliminates the need for routine aPTT monitoring, and yields more predictable anticoagulation. 14

Contraindications

• Heparin must be avoided in patients with heparin‑induced thrombocytopenia; a direct thrombin inhibitor should be used instead. 13